Patents
Literature
Patsnap Eureka AI that helps you search prior art, draft patents, and assess FTO risks, powered by patent and scientific literature data.

138 results about "Macrogol" patented technology

Macrogol, also known as polyethylene glycol (PEG), is used as a medication to treat constipation in children and adults. It is also used to empty the bowels before a colonoscopy. It is taken by mouth. Benefits usually occur within three days. Generally it is only recommended for up to two weeks.

Macrophage membrane coated ROS responsive bionic nano drug delivery system, preparation and application

The invention relates to the field of traditional Chinese medicine effective component new dosage form pharmaceutical preparations, and discloses an M2 type macrophage membrane coated ROS responsive bionic nano drug delivery system, preparation and application. Mesoporous silica is used as a core to load a traditional Chinese medicine effective component, namely tripterine, and lipid components, namely PEGylated distearoyl phosphatidyl ethanolamine (DSPE-PEG), dioleoyl lecithin (DOPC), cholesterol and the like, are used as raw materials to prepare a ROS-responsive lipid coating, so that ROS-responsive tripterine mesoporous silica is formed. And then realizing bionic fusion with the M2 type macrophage membrane on the outer layer through an ultrasonic coating technology to prepare the M2 type macrophage membrane coated ROS responsive bionic mesoporous silica nano drug delivery system. The invention can realize targeted therapy of rheumatoid arthritis, and has the advantages of biological safety and the like.
Owner:MACAU UNIV OF SCI & TECH

Biomineralization material for treating dentin hypersensitivity and promoting epitaxial growth of enamel, and use thereof

The provided is a biomineralization material for treating dentin hypersensitivity and promoting epitaxial growth of enamel and a use thereof. The biomineralization material includes following raw materials in parts by weight: 5-72 parts of a film-forming protein or a PEGylated film-forming protein, 4-67 parts of a water-soluble disulfide bond exchanger and 1-21 parts of a pH regulator. The present application proposes for the first time that the disulfide bond exchanger (e.g., cysteine (Cys)) without any toxicity may react with the film-forming protein or PEGylated film-forming protein. When a protein nano-coating with a mineralization regulating function is formed, no large number of macromolecular protein aggregates can be generated to block the dentin pores. The biomineralization material can permeate deeply into the exposed dentin pores, with the depth of 200-500 μm (the sealing depth of the protein coating reacting with TCEP is only about 40 μm).
Owner:SHAANXI NORMAL UNIV

Hydrogel composition as well as preparation method and application thereof

The invention discloses a hydrogel composition as well as a preparation method and application thereof, a spray fluidized bed granulation technology is adopted, kudzu vine root extract-polyethylene glycol dispersoid is sprayed on the surfaces of hydrogel particles in a high-pressure atomization manner, and the hydrogel composition is obtained through cold air curing. The problem that the uniformity is poor when the puerarin extract and hydrogel particles are directly mixed is solved, the prepared hydrogel composition can effectively absorb ethyl alcohol, contact between ethyl alcohol and gastrointestinal mucosa is reduced, meanwhile, puerarin is released, and the effects of dispelling the effects of alcohol and protecting the liver are achieved.
Owner:SHANGHAI PANDA MEDICAL CO LTD +1

Bionic vesicle preparation as well as preparation method and application thereof

The invention belongs to the technical field of bionic nano-drugs, and particularly relates to a bionic vesicle preparation as well as a preparation method and application thereof. The bionic vesicle preparation disclosed by the invention is prepared from the following raw materials: mesenchymal stem cell outer vesicles, nintedanib and DSPE-PEG-HA (hyaluronic acid modified pegylated phospholipid); the nintedanib is loaded in the mesenchymal stem cell outer vesicle, and the DSPE-PEG-HA is coupled to the surface of the mesenchymal stem cell outer vesicle. The bionic vesicle preparation disclosed by the invention can be used for directly delivering a drug to a pulmonary fibrosis injury part through inhalation type drug delivery, and acting on a focus part at a higher local concentration, meanwhile, the exposure of the drug in whole-body circulation is remarkably reduced, the occurrence of side effects is reduced, and the specific targeting intervention and regulation on fibroblasts are realized.
Owner:LUOYANG CENT HOSPITAL

Pegylated liposomes and methods of use

Provided herein are PEGylated liposomes, and methods of making and using thereof. The PEGylated liposomes comprise at least a cholesterol, a non-PEGylated neutral lipid, and a PEGylated lipid, wherein the average molecular weight of the PEG component in the PEGylated lipid is about 5000 Daltons or less. The PEGylated liposomes are stable and capable of delivery of an agent for the generation of an immune response, for example an agent for vaccine, therapeutic, or diagnostic uses. Compositions and methods related to making the PEGylated liposomes and using the PEGylated liposomes for stimulating an immune response are also provided.
Owner:UNIV OF VIRGINIA PATENT FOUND +1

Bone regeneration in compromised wounds

Biomaterials disclosed herein can comprise a hydrogel comprising PEG, gelatin, and a glycosaminoglycan with sulfated moiety; and chondrogenic, osteogenic, and immunomodulatory cytokines; wherein the biomaterial is capable of potentiating bone regeneration in a compromised wound while reducing inflammatory response. The glycosaminoglycan with sulfated moiety can comprise heparin, heparan sulfate, keratin sulfate, chondroitin sulfate, dermatan sulfate, and / or similar materials. The biomaterial can further comprise mesenchymal stem cells (MSCs), a crosslinking initiator, microparticles and nanoparticles, and or other materials. The biomaterial can be injectable into a wound, or the biomaterial can be loaded in, or further comprise a porous scaffold providing mechanical support for other components of the biomaterial, such that it can be implanted into a wound.
Owner:UNIV OF PITTSBURGH OF THE COMMONWEALTH SYST OF HIGHER EDUCATION

Allicin oleogel as well as preparation method and application thereof

The invention discloses allicin oleogel as well as a preparation method and application thereof, and belongs to the technical field of medicines. The allicin oleogel is prepared from the following raw materials: allicin, an oil phase, a gelator and a surfactant, the gelator comprises beeswax and / or fruit wax; the surfactant comprises one or more of caprylic / capric polyethylene glycol glyceride, Tween 20 and polyglycerol fatty acid ester. The gel factor forms oil gel through crystal self-assembly, allicin is solidified and intercepted in the oil gel, the gel factor is optimized, and a surfactant is used in a matched manner, so that a release behavior similar to that of a mixed solution of free allicin and an oil phase can be obtained, and the transdermal release rate is improved. The allicin oil gel can effectively entrap allicin, cover the peculiar smell of the allicin and improve the stability of the allicin, and through abdominal transdermal administration, the medicine accumulation amount in subcutaneous adipose tissues is remarkably increased, and the treatment effect on obesity and complications thereof can be improved.
Owner:ZHONGSHAN INST FOR DRUG DISCOVERY SHANGHAI INST OF MATERIA MEDICA CHINESE ACAD OF SCI

Temperature-sensitive injectable pedunculoside hydrogel as well as preparation method and application of temperature-sensitive injectable pedunculoside hydrogel

The invention relates to the technical field of medicines, and discloses pedunculoside temperature-sensitive injectable hydrogel as well as a preparation method and application thereof. Specifically, the invention provides application of the temperature-sensitive injectable hydrogel with the pedunculoside in preparation of the medicine for treating the cardiovascular diseases, and the temperature-sensitive injectable hydrogel with the pedunculoside comprises the pedunculoside, a lactic acid-glycolic acid copolymer, polyvinyl alcohol and dipolylactic acid-glycolic acid copolymer polyethylene glycol. The microsphere-gel combined delivery preparation PE-M / Ge prepared by the preparation method disclosed by the invention is good in injectability and has a good temperature-sensitive gelling characteristic in vitro; the obvious gel property is realized, and the microspheres are uniformly distributed in the gel; the release of the drug can be effectively reduced, the release curve is closer to zero-order release, the dual controlled release system can more stably release the drug, the toxic and side effects caused by non-characteristic distribution of PE are reduced, and the bioavailability is improved. And the PE-M / Ge has no cytotoxicity to H9c2 cells and HUVECs cells, so that a foundation is laid for in-vivo pharmacodynamic experiments of rats.
Owner:LISHUI UNIV

PH response bionic nano system for enhancing photodynamic therapy, preparation and application

PendingCN119112838Agood grafting rateHas pH responsive propertiesCell dissociation methodsAntipyreticTherapeutic effectEndogeny
The invention provides a pH response bionic nano system for enhancing photodynamic therapy, preparation and application, and belongs to the field of pharmaceutical preparations, hyaluronic acid is used as an initial carrier to load an endogenous hydrogen sulfide donor SPRC and modify an acid response connexon, and then the hyaluronic acid is crosslinked with a pegylated photosensitizer Ce6 to form acid response nano particles. And finally, coating nano particles with the macrophage membrane through a nano-membrane co-extrusion technology to prepare the pH response type bionic nano system (RAW-HSC) coated with the macrophage membrane. In-vivo and in-vitro experiments show that the pH response type bionic nano system can effectively target an inflammation joint part, a small amount of hydrogen sulfide generated by SPRC release can effectively enhance the photodynamic therapy effect, meanwhile, the pH response type bionic nano system has the advantages of biological safety, pH response release and the like, a new thought is provided for research, development and design of a novel medicament, and the pH response type bionic nano system has wide application prospects. The important significance is realized on the treatment of rheumatoid arthritis.
Owner:MACAU UNIV OF SCI & TECH

Pegylated liposomes and methods of use

Provided herein are PEGylated liposomes, and methods of making and using thereof. The PEGylated liposomes comprise at least a cholesterol, a non-PEGylated neutral lipid, and a PEGylated lipid, wherein the average molecular weight of the PEG component in the PEGylated lipid is about 5000 Daltons or less. The PEGylated liposomes are stable and capable of delivery of an agent for the generation of an immune response, for example an agent for vaccine, therapeutic, or diagnostic uses. Compositions and methods related to making the PEGylated liposomes and using the PEGylated liposomes for stimulating an immune response are also provided.
Owner:UNIV OF VIRGINIA PATENT FOUND +1

Application of adenosine deaminase or modifier of adenosine deaminase in preparation of medicine for treating diabetic nephropathy

The invention discloses application of adenosine deaminase or a modifier thereof in preparation of a medicine for treating diabetic nephropathy. After intraperitoneal injection treatment of polyethylene glycol modified escherichia coli expressed mouse adenosine deaminase is carried out on a mouse with diabetic nephropathy, the damage degree of the kidney of the mouse is obviously weakened. According to the invention, the adenosine deaminase or the modifier thereof has an obvious treatment effect on the type 2 diabetic nephropathy for the first time, and the adenosine deaminase and the modifier thereof have potential application prospects in preparation of the medicines for treating the type 2 diabetic nephropathy.
Owner:NANJING UNIV OF SCI & TECH

Application of pegylated irinotecan in treatment of triple negative breast cancer disease

The invention discloses an application of pegylated irinotecan in preparation of a medicine for preventing and / or treating triple-negative breast cancer brain metastasis diseases, which is shown by in-vivo imaging observation and lifetime observation of high, medium and low dose groups of pegylated irinotecan with a specific structure. The high-dose group, the medium-dose group and the low-dose group all have a definite anti-tumor effect, bioluminescence signal values are inhibited to different degrees, the lifetime is prolonged, and the lifetime of the high-dose group and the lifetime of the medium-dose group are remarkably longer than that of the NKTR-102 group.
Owner:JENKEM TECH CO LTD TIANJIN

Calcium carbonate / vitamin D3 composition and preparation method thereof

The invention discloses a vitamin D3-polyethylene glycol composition and a preparation method thereof, the vitamin D3-polyethylene glycol composition comprises vitamin D3, a dispersion medium, an adsorbent and polyethylene glycol, the vitamin D3 is dissolved in the dispersion medium, the adsorbent is used for adsorption, and then the mixture is added into hot-melt polyethylene glycol for dispersion to obtain the vitamin D3-polyethylene glycol composition. The dosage of the polyethylene glycol is controlled to be 70%-90% of that of the vitamin D3-polyethylene glycol composition; the vitamin D3 in the calcium carbonate / vitamin D3 pharmaceutical composition prepared by the invention has excellent long-term stability, and also has good mixing uniformity and content uniformity; the preparation process is simple, the vitamin D3 and other auxiliary materials do not need to be prepared into large particles in advance, the particles are easy to transfer without freeze-drying, the material loss is less, and the preparation method is suitable for industrialization.
Owner:HANGZHOU BIO SINCERITY PHARMA TECH CO LTD +1

A delivery carrier for targeted pituitary drug delivery and its preparation method and application

The present invention discloses a delivery carrier for targeted pituitary drug delivery and its preparation method and application. The present invention designs a carrier that can target the pituitary for drug delivery, and treats patients with spinocerebellar disorders, hypothalamic hypothyroidism, congenital single thyrotropin-releasing hormone (TRH) deficiency, non-alcoholic fatty liver disease (NAFLD), etc. The present invention modifies TRH (TRH-PEG-LP) on the surface of a PEGylated lipid carrier (PEG-LP), injects the TRH-PEG-LP carrier loaded with a near-infrared fluorescent dye (DiR) into the mouse body through the tail vein for 2 hours, takes the pituitary tissue, and observes the color development of the fluorescent dye in the pituitary of the mouse under a small animal imager (Ex / Em: 748 / 780nm), and finds that the carrier modified by TRH can target pituitary tissue well. TRH modification on the surface of the PEGylated lipid carrier can play a role in targeted delivery, and TRH can bind to the TRH receptor specifically expressed on the surface of the pituitary cells, thereby realizing targeted drug delivery of the pituitary.
Owner:NANJING DRUM TOWER HOSPITAL

Biodegradable lung sealants

PendingUS20260183331A1High molecular massBiochemistry
The invention relates to a rapid setting liquid lung sealant that forms a highly adherent and elastic hydrogel. Provided are lung sealants comprising two high molecular weight (20 kDa) multi-arm PEG compositions wherein the first PEG composition includes an alkaline buffer and the second PEG composition includes a mildly acidic buffer for optimized set up time and extended working time. In some embodiments, the PEGs further comprise a radioprotectant such as tocopherol. In some embodiments, a colorant is added to one or both PEGs of the lung sealant to improve visualization of the lung sealant against human lung tissue.
Owner:ETHICON INC

Bulking hemostatic tablets containing oxidized regenerated cellulose

The present invention relates to compressed hemostatic tablets or forms comprising a fibrous nonwoven oxidized cellulose (OC or ORC) multilayer material compressed into a shape-stable tablet, further comprising a calcium salt, and capable of rapidly expanding upon contact with blood or plasma. The compressed forms may further comprise multi-arm PEG-SG and are dimensionally stable, preferably in terms of length and width, for at least 48 hours after compression. In some embodiments, upon contact with blood, the compressed forms expand to 1.5 to 5 times their tablet length in 5 seconds, to 2 to 6 times their tablet length in 20 seconds, and to 3 to 6 times their tablet length in 5 minutes. The compressed forms are effective for hemostasis in heparinized blood.
Owner:ETHICON INC

Milk extracellular vesicle enrichment process using peg

The invention relates to a process for obtaining a milk extracellular vesicle (EV)- enriched product from whey by mixing whey with a PEG solution providing a whey- PEG mixture; and centrifuging the whey-PEG mixture providing a pellet enriched in milk EV.
Owner:FRIESLANDCAMPINA NEDERLAND BV

Ophthalmic compositions containing a nitric oxide releasing prostamide

Present invention provides aqueous ophthalmic compositions in the form of solution comprising hexanoic acid, 6-(nitrooxy)-, (1S,2E)-3-[(1R,2R,3S,5R)-2-[(2Z)-7-(ethylamino)-7-oxo-2-hepten-1-yl]-3,5-dihydroxycyclopentyl]-1-(2-phenylethyl)-2-propen-1-yl ester and macrogol 15 hydroxystearate as the only solubilizing agent, and a method for their preparation.
Owner:NICOXS A

Nanoemulsion composition of curcumin for the treatment of inflammatory bowel diseases

Nanoemulsion composition for the treatment of inflammatory bowel diseases, comprising: a) 1.0% (w / w) curcumin as active pharmaceutical ingredient; b) 10.0% w / w Caprylic / Capric triglycerides as oil phase; c) 15.0% w / w Tween 80 as surfactant; d) 10.0% w / w PEG 400 as co-surfactant; e) 2.0% w / w lecithin as emulsifier; f) 2.0% w / w ethanol as a solubilizer; and g) distilled water qs to 100 w / w, h) wherein the composition forms a nanoemulsion having a mean particle size in the range of 90-120 nm and a polydispersity index of less than 0.3 and provides sustained curcumin release for at least 12 hours in simulated intestinal fluid.
Owner:AGARWAL VIKAS DR JAIPUR +9

TREATMENT PROCEDURES WITH PEGFILTRISTIM AND ROMIPLOSTIM

ActiveDE602019080091T2Peptide/protein ingredientsBlood disorderPeginterferon alfa-2bRomiplostim
Owner:AMGEN INC

Pegylated liposomes and uses thereof

Provided herein are PEGylated liposomes, and methods of making and using thereof. The PEGylated liposomes comprise DSPE-peg2000 and nosiheptide in a molar ratio of 3:1. Compositions and methods which is related to making the PEGylated liposomes and using the PEGylated liposomes for preventing or treating bacterial infection are also provided.
Owner:LT BIOPHARMA INC

Self-assembled diblock copolymers composed of pegmema and drug bearing polymeric segments

This invention relates to polymer drug conjugates according to formula I, and their use for treatment of diseases such as cancer.
Owner:RS ARASTIRMA EGITIM DANISMANLIK ILAC SANAYI TICARET ANONIM SIRKETI

GLP-1 derivative and preparation method thereof

The invention belongs to the field of medicine synthesis, and particularly relates to a series of GLP-1 derivatives and a preparation method thereof. The GLP-1 derivative comprises a polypeptide part, a linker part and a side chain part, the amino acid sequence of the polypeptide part is as follows: H-X-E-G-T-F-T-S-D-V-S-S-Y-L-E-G-Q-A-A-K-E-F-I-A-W-L-V-R-G-R-G; the amino acid sequence of the polypeptide part is Wherein X is alpha-aminoisobutyric acid; the structure of a linker part of the GLP-1 derivative is oligomeric ethylene glycol-oligomeric ethylene glycol-glutamic acid; the side chain part of the GLP-1 derivative is composed of two sections of short-chain fatty acids linked by 2, 6-diaminocaproic acid. The GLP-1 derivative prepared by the invention can be combined with a GLP-1 receptor and activate the receptor, so that the compound has extremely high application potential in treatment of metabolic diseases such as type 2 diabetes mellitus and obesity.
Owner:CHENQUE (HANGZHOU) BIOTECHNOLOGY CO LTD

Methods of treatment with pegfilgrastim and romiplostim

The present invention concerns methods comprising co-administration of pegfilgrastim and romiplostim for treatment of diseases and conditions characterized by low neutrophil levels (neutropenia) and / or low platelet levels (thrombocytopenia). The present invention concerns an enhanced effect on neutrophil levels and on platelet levels resulting from co-administration of pegfilgrastim and romiplostim. The present invention further concerns a method of treating a patient who has been exposed to radiation, which comprises administering romiplostim at a dose of about 1 to about 10 g / kg. The invention further concerns such methods wherein a single dose of romiplostim is administered to the patient and wherein romiplostim is administered about 24 hours or less after the radiation exposure. The invention further concerns treatment with romiplostim and pegfilgrastim for radiation exposure. Such methods relate to treatment of acute radiation syndrome and treatment to counteract the effects of radiation therapy and other sources of radiation exposure.
Owner:AMGEN INC

Ophthalmic compositions containing a nitric oxide releasing prostamide

The present invention provides aqueous ophthalmic compositions in the form of solution comprising hexanoic acid, 6-(nitrooxy)-, (1S,2E)-3-[(1R,2R,3S,5R)-2-[(2Z)-7-(ethylamino)-7-oxo-2-hepten-1-yl]-3,5-dihydroxycyclopentyl]-1-(2-phenylethyl)-2-propen-1-yl ester and macrogol 15 hydroxystearate as the only solubilizing agent, and a method for their preparation.
Owner:NICOX SA

Application of gelatinized intestinal epithelial cells in preparation of medicine for treating inflammatory bowel disease

The invention discloses an application of gelatinized intestinal epithelial cells in preparation of drugs for treating inflammatory bowel disease, the gelatinized intestinal epithelial cells take mouse intestinal epithelial cells as cores, poly (ethylene glycol) diacrylate, a photoinitiator and poly-L-lysine permeate into the cells through low-temperature freeze thawing, and an intracellular porous hydrogel skeleton is formed through ultraviolet crosslinking. The gelated intestinal epithelial cell has a strong cfDNA and inflammatory factor removal function, has good biocompatibility, has no direct or indirect toxic effect on a human body, has no potential toxicity, and can be used for treating inflammatory bowel diseases.
Owner:HEFEI UNIV OF TECH

Pegylated sirolimus and application thereof

PendingCN121445883AOrganic active ingredientsPowder deliveryBiological half-lifeNanoparticle
The invention belongs to the technical field of biological medicine, and relates to a releasable pegylated sirolimus compound and application thereof. The invention provides a releasable PEGylated sirolimus compound. The compound can be self-assembled to form micelles, prepared into nanoparticles and targeted to immune cells, regulates the release behavior of drugs, reduces the system toxicity and prolongs the biological half-life period. And moreover, the sirolimus-hydrophilic PEG conjugate has a proper hydrophobic sirolimus end and a hydrophilic PEG chain end, can effectively release drugs in immune cells, and is a good carrier for preparing nanoparticles. The invention provides a releasable PEGylated sirolimus compound, a nano-drug and a pharmaceutical composition prepared from the releasable PEGylated sirolimus compound, and application of the releasable PEGylated sirolimus compound in preparation of drugs for reducing immune response.
Owner:CHONGQING PEG BIO BIOTECH CO LTD